




TWILIGHT LITAKA PHARMA LIMITED

Regd. Office : Himalaya Estate, 16-A Shivajinagar, Pune 411 005

UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 30TH JUNE, 2010

| Sr. No. | Particulars | (Rs. in Lacs) | | |
|---------|---|-----------------|----------------|----------------------|
| | | Quarter Ended | | Financial Year Ended |
| | | (Unaudited) | | (Unaudited) |
| | | 30.06.2010 | 30.06.2009 | 31.03.2010 |
| 1 | a. Net Sales / Income From Operations | 15185.06 | 10384.99 | 49196.23 |
| | b. Other Operating Income | - | - | - |
| 2 | Expenditure | | | |
| | a Increase/decrease in stock in trade & WIP | -297.26 | -118.08 | -1006.72 |
| | b Consumption of Raw material | 11009.73 | 7589.60 | 35192.86 |
| | c Purchase of traded goods. | 1102.96 | 523.37 | 3691.29 |
| | d Employee cost | 421.80 | 346.93 | 1612.93 |
| | e Depreciation | 88.51 | 75.42 | 308.67 |
| | f Other expenditure | 827.21 | 681.56 | 3469.66 |
| | g Expenditure (a to f) | 13152.95 | 9098.80 | 43268.69 |
| 3 | Profit from Operations before Other Income, Interest and Exceptional Items (1-2) | 2032.11 | 1286.19 | 5927.54 |
| 4 | Other Income | 39.44 | 31.35 | 242.65 |
| 5 | Profit before Interest & Exceptional Items (3+4) | 2071.55 | 1317.54 | 6170.19 |
| 6 | Interest | 549.92 | 475.35 | 2115.35 |
| 7 | Profit after Interest, but before Exceptional Items (5-6) | 1521.63 | 842.19 | 4054.84 |
| 8 | Exceptional Items | - | - | - |
| 9 | Profit from Ordinary Activities before tax (7+8) | 1521.63 | 842.19 | 4054.84 |
| 10 | Tax Expenses | 269.00 | 129.00 | 717.00 |
| 11 | Profit from Ordinary Activities after tax (9-10) | 1252.63 | 713.19 | 3337.84 |
| 12 | Extraordinary items (net of tax expense) | - | - | - |
| 13 | Net Profit for the period | 1,252.63 | 713.19 | 3,337.84 |
| 14 | Paid-up Equity Share Capital (Equity share of Rs.5/- each) | 1064.06 | 1064.06 | 1064.06 |
| 15 | Reserve excluding revaluation reserves | 9923.32 | 6046.04 | 8670.69 |
| 16 | Earning per share (EPS) | | | |
| | a. Basic and diluted EPS before extraordinary items for the period | *5.89 | *3.35 | 15.68 |
| | b. Basic and diluted EPS after extraordinary items for the period. | *5.89 | *3.35 | 15.68 |
| 17 | Aggregate of non promoter shareholding | | | |
| | number of shares | 7777036 | 7716036 | 7767036 |
| | percentage of shareholding | 36.54 | 36.26 | 36.50 |
| 18 | Promoters and Promoters Group shareholding | | | |
| | a) Pledged / Encumbered | | | |
| | - Number of shares | 5781588 | 5781588 | 5781588 |
| | - Percentage of shares (as % to the total shareholding of promoters & promoters group) | 42.81 | 42.62 | 42.62 |
| | - Percentage of shares (as % to the total share capital of the Company) | 27.17 | 27.17 | 27.17 |
| | b) Non Encumbered | | | |
| | - Number of shares | 7722661 | 7783661 | 7732661 |
| | - Percentage of shares (as % to the total shareholding of promoters & promoters group) | 57.19 | 57.38 | 57.38 |
| | - Percentage of shares (as % to the total share capital of the Company) | 36.29 | 36.57 | 36.57 |



* not annualised

Notes :

- 1) The above unaudited results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13th August, 2010.
- 2) Provision for Tax includes Current Year Tax and Deferred Tax
- 3) The Company is primarily engaged in Pharmaceutical formulations business, which in the context of Accounting Standard (AS17) "Segment Reporting" is considered to be the only business segment.
- 4) In respect of outstanding derivative contracts in foreign currency, provision existing for fall in market value is considered adequate as at the quarter ending 30th June, 2010
- 5) On 13th March, 2010 Company has allotted 35,00,000 Convertible Warrants at Rs. 86/- each to the applicants as per terms of issue. These warrants are convertible into Equity Shares of the Company within a period of 18 months from the date of their allotment at the option of warrants holders.
- 6) The Company has entered into "Share Purchase Agreement" with Briocia Pharma (India) Pvt. Ltd. on 28th April, 2010. As per the said Agreement, Briocia Pharma (India) Pvt. Ltd. will become 100% subsidiary of the Company after completion of relevant legal formalities.
- 7) The above results are subject to Limited Review by the Statutory Auditors of the Company pursuant to Clause 41 of the Listing Agreement.
- 8) Previous year's figures have been regrouped and rearranged wherever necessary.
- 9) During the current quarter, four investor complaints were received. There was no pending investor complaint at the beginning of the quarter and at the end of the quarter.

Place : Pune
Date : 13th August, 2010

For TWILIGHT LITAKA PHARMA LIMITED
GOPAL RAMOURTI
Managing Director